CONSOLIDATED STATEMENTS OF INCOME (USD $) In Thousands, except Per Share data, unless otherwise specified	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Revenue:
Net product sales	$ 4,699,690	$ 3,508,438	$ 2,567,354
Collaborative agreements and other revenue	19,500	10,540	13,743
Royalty revenue	122,880	106,767	108,796
Total revenue	4,842,070	3,625,745	2,689,893
Expenses:
Cost of goods sold (excluding amortization of acquired intangible assets)	425,859	306,521	216,289
Research and development	1,600,264	1,128,495	794,848
Selling, general and administrative	1,226,314	950,634	753,827
Amortization of acquired intangible assets	289,226	203,231	83,403
Acquisition related (gains) charges and restructuring, net	(142,346)	47,229
Total costs and expenses	3,399,317	2,636,110	1,848,367
Operating income	1,442,753	989,635	841,526
Other income and expense:
Interest and investment income, net	25,860	44,757	76,785
Equity in (losses) of affiliated companies	(2,804)	(1,928)	(1,103)
Interest (expense)	(42,737)	(12,634)	(1,966)
Other income (expense), net	(3,550)	(7,220)	60,461
Income before income taxes	1,419,522	1,012,610	975,703
Income tax provision	102,066	132,418	198,956
Net income	1,317,456	880,192	776,747
Less: Net loss attributable to non-controlling interest	694	320
Net income attributable to Celgene	$ 1,318,150	$ 880,512	$ 776,747
Net income per share attributable to Celgene:
Basic (in dollars per share)	$ 2.89	$ 1.90	$ 1.69
Diluted (in dollars per share)	$ 2.85	$ 1.88	$ 1.66
Weighted average shares:
Basic (in shares)	455,348	462,298	459,304
Diluted (in shares)	462,748	469,517	467,354